Acute Interstitial Nephritis (AIN): Student Handout
Learning Objectives
By the end of this handout, you should be able to: - Recognize AIN as a major cause of AKI (accounting for 15-27% of cases) - Identify drug and non-drug causes of AIN - Understand the pathophysiology of drug-induced immune-mediated AIN - Recognize diagnostic limitations and pitfalls - Interpret urinalysis and novel biomarkers - Distinguish AIN from acute tubular necrosis - Recognize TINU syndrome (tubulointerstitial nephritis + uveitis) - Implement appropriate diagnostic and therapeutic approaches
Definition and Epidemiology
Acute Interstitial Nephritis: Immune-mediated inflammatory response affecting the kidney tubulointerstitium (interstitial space and tubules), sparing glomeruli (in primary AIN).
Incidence: - Accounts for 15-27% of kidney biopsies performed for unexplained AKI - Represents 1-3% of all AKI in general population - 70-75% are drug-induced (medication-related)
Mortality & Morbidity: - In-hospital mortality: ~20% of severe cases requiring dialysis - Many patients progress to chronic kidney disease if untreated - Early recognition and intervention critical for outcomes
Pathophysiology: The Immune Mechanism
The Pathogenic Process
Step 1: Initial Injury - Medication acts as hapten (chemical conjugates with protein) - Creates neo-antigen complex recognized as “foreign”
Step 2: Sensitization - Antigen-presenting cells process the hapten-protein complex - Helper T cells become activated - T cell–mediated hypersensitivity reaction develops
Step 3: Inflammatory Infiltrate - Lymphocytes (predominantly T cells) infiltrate interstitium - Eosinophils may be present (but inconsistently) - Inflammatory cytokines cause cellular injury
Step 4: Tubulointerstitial Damage - Tubule epithelial cells injured first - Interstitial edema and inflammation develop - Progressive fibrosis if untreated
Key Feature: Primary damage is immune-mediated, not dose-dependent. This explains why AIN can occur at therapeutic doses and after brief exposure.
Causes: Drug and Non-Drug Etiologies
Drug-Induced AIN (Most Common Cause)
Most Common Drug Causes (In Descending Frequency):
| Drug Class | Examples | Frequency |
|---|---|---|
| Antibiotics | Amoxicillin, ciprofloxacin, TMP-SMX, cephalosporins | 49% of drug-induced AIN |
| Proton pump inhibitors | Omeprazole, pantoprazole, lansoprazole | 14% of drug-induced AIN |
| NSAIDs | Ibuprofen, naproxen, indomethacin | 11% of drug-induced AIN |
| Diuretics | Thiazides, furosemide | ~5% |
| Anticonvulsants | Phenytoin, carbamazepine, allopurinol | Rare |
| Biologics | TNF-alpha inhibitors, monoclonal antibodies | Emerging cause |
Timing Patterns: - Antibiotics: Early onset (typically first 1-2 weeks) - NSAIDs: Intermediate timing (weeks 2-4) - PPIs: Delayed onset (weeks 3-8 or even months of exposure)
Clinical Presentation: The Classic Triad Is Uncommon
Classic Triad (Absent in ~2/3 of Cases)
- Fever (~20-30% of patients)
- Rash (~25% of patients)
- Eosinophilia (~20% of patients)
Critical Point: The absence of the classic triad does NOT exclude AIN. Many patients have AIN without any of these findings.
More Common Presentation
Most Typical Scenario: - Nonoliguric AKI (preserved or only mildly reduced urine output despite rising creatinine) - AKI developing days to weeks after new medication initiation - Bland or nonspecific symptoms (fatigue, anorexia, nausea) - Physical exam unremarkable (no fever, no rash visible)
Clinical Pearl: The key clue is nonoliguric AKI temporally related to new medication—this should raise high suspicion for AIN.
Diagnostic Approach: Urinalysis Findings
Urinalysis Pattern in AIN
| Finding | Typical Pattern | Significance |
|---|---|---|
| Proteinuria | Mild (usually <1-2 g/day) | Heavy proteinuria suggests glomerular disease |
| Hematuria | Mild to moderate | RBCs and WBCs present |
| Leukocyte esterase | 2+ (positive) | Indicates WBCs in urine |
| WBC count | Elevated (>5/hpf, often 13-138/µL) | Strong finding in AIN |
| WBC casts | May be present | Support diagnosis but not required |
| RBC casts | Absent (or rare) | Suggests GN instead; if present, consider dual pathology |
Urine Microscopy Interpretation
Characteristic Pattern: - Numerous WBCs without bacteria (sterile pyuria) - Occasional RBCs - White cell casts when present - Mild proteinuria - ABSENCE of RBC casts (helps differentiate from glomerulonephritis)
Important Distinction: - RBC casts = GN/RPGN (glomerular disease) - WBC casts = AIN (interstitial disease) - Muddy brown casts = ATN (tubular disease)
Tests That DON’T Help (Important Limitations)
Urine Eosinophils: - Historically considered diagnostic for AIN - Recent evidence: NO diagnostic utility - Poor sensitivity (<50%) and specificity (<50%) - Should NOT be ordered as diagnostic test for AIN - Not recommended in current practice guidelines
Peripheral Eosinophilia: - Occurs in only minority of drug-induced AIN cases - Absence doesn’t exclude diagnosis - No diagnostic value as screening test
Novel Diagnostic Biomarkers
Beta-2 Microglobulin (B2M)
What It Is: Low-molecular-weight protein freely filtered and reabsorbed by proximal tubule. Elevation indicates tubular dysfunction.
Why It’s Mentioned: Historically discussed as AIN marker, but limited utility for general AIN diagnosis.
Current Role: - Moderate utility for TINU syndrome (tubulointerstitial nephritis + uveitis) - Limited for differentiation of AIN from ATN (both cause elevated B2M) - Pre-analytical instability (degrades at pH <6.0) limits reliability
Bottom Line: B2M is outdated for general AIN diagnosis; newer biomarkers superior.
CXCL9: The Emerging Gold Standard
What It Is: C-X-C motif chemokine ligand 9—a T cell–recruiting chemokine directly involved in immune response.
Why It’s Revolutionary: - Directly mechanistically linked to T cell–mediated inflammation (the actual AIN pathophysiology) - Not elevated in ATN (unlike B2M, NGAL) - Excellent stability (remains stable >24 hours at room temperature) - Fewer pre-analytical issues
Diagnostic Performance: | Metric | Value | |——–|——-| | AUC for AIN vs ATN | 0.84-0.95 (excellent) | | Sensitivity | 85-92% | | Specificity | 80-92% | | Outperforms all traditional biomarkers | YES |
Cutoff Interpretation: - High CXCL9 supports AIN diagnosis - Can distinguish AIN from other AKI causes - Increasingly available in specialized centers
Clinical Pearl: CXCL9 is the future of non-invasive AIN diagnosis; traditional markers (urinary eosinophils) are outdated.
Kidney Biopsy: Definitive Diagnosis
Indication: When clinical diagnosis uncertain and diagnosis would change management.
Histologic Findings: - Dense lymphoplasmacytic infiltration of interstitium - Sparing of glomeruli (primary AIN) - Eosinophils may or may not be present - Tubular epithelial cell injury - Possible interstitial edema
Timing: Biopsy within 2-3 weeks of symptom onset optimal for diagnosis and prognosis assessment.
Not Always Necessary: In obvious cases (classic timeline + medication history + urinalysis pattern + clinical context), biopsy may be deferred if patient improving with drug discontinuation.
TINU Syndrome: A Special Entity
Definition and Epidemiology
TINU = Tubulointerstitial Nephritis + Uveitis Syndrome
Key Statistics: - Represents ~1-2% of uveitis cases in specialized centers - NOT just a pediatric disease: Affects patients aged 9-76 years - Female predominance (3:1 ratio) - Often misdiagnosed as isolated uveitis or drug-induced AIN alone
Important Note: Historical literature emphasized adolescent presentation; modern recognition shows substantial adult involvement (30-40% of cases are adults).
Clinical Presentation
Dual System Involvement: 1. Renal: Acute interstitial nephritis (elevated creatinine, pyuria, RBC+WBC casts possible) 2. Ocular: Bilateral anterior uveitis (eye pain, photophobia, visual symptoms) 3. Systemic: Often nonspecific (fever, malaise, arthralgia)
Timeline: - Simultaneous presentation common - Ocular findings may precede renal manifestations (diagnosed as isolated uveitis first) - Renal manifestations may occur months after ocular symptoms
Diagnostic Criteria
Definite TINU: 1. Kidney biopsy confirming AIN 2. Bilateral anterior uveitis on ophthalmology exam 3. No other systemic disease explaining both
Probable TINU: 1. Clinical AIN (elevated Cr + compatible urinalysis; biopsy not required if clinical picture clear) 2. Bilateral anterior uveitis confirmed 3. No alternative diagnosis
Role of B2M in TINU
This is where B2M has established utility: In TINU syndrome specifically, urinary B2M has superior sensitivity/specificity compared to general AIN.
Performance in TINU: - Sensitivity: 88-100% - Specificity: 70-80% - Elevated B2M + bilateral uveitis = high probability TINU
Practical Application: - Screen for bilateral anterior uveitis in any patient with AKI (ophthalmology exam) - If uveitis present + elevated B2M, TINU diagnosis highly likely - Refer to rheumatology/immunology for systemic workup
Management Principles
Immediate Steps
1. Discontinue Offending Medication - Most critical intervention - Discontinue as soon as AIN suspected - Many cases improve significantly with drug withdrawal alone
2. Supportive Care - Fluid and electrolyte management - Renal function monitoring - RRT if necessary (same indications as ATN)
Corticosteroid Therapy
Evidence & Recommendation: - Corticosteroids may improve outcomes if started early (within 2-3 weeks) - Typical regimen: Prednisone 0.5-1 mg/kg/day (or IV methylprednisolone in severe cases) - Duration: Usually 2-4 weeks with taper
Outcome Data: - 49% complete recovery (creatinine returns to baseline) - 39% partial recovery (improved but not to baseline) - 12% no recovery (permanent renal impairment)
Factors Associated with Better Outcomes: - Earlier steroid initiation (within 1-2 weeks) - Shorter duration of drug exposure before diagnosis - Lower peak creatinine at presentation
Clinical Pearl: If biopsied early and treated with steroids early, outcomes improve; delayed diagnosis/treatment associated with permanent renal damage.
When to Escalate to Immunosuppression
Some cases with severe AIN or inadequate response to steroids may require: - Mycophenolate mofetil (MMF) - Tacrolimus - Other immunosuppressive agents - Typically reserved for severe/refractory cases
Differential Diagnosis: AIN vs. ATN vs. RPGN
| Feature | AIN | ATN | RPGN |
|---|---|---|---|
| Mechanism | Immune-mediated inflammation | Tubular necrosis | Glomerular crescents |
| Urine output | Nonoliguric (preserved) | Oliguric or nonoliguric | Often oliguric |
| Proteinuria | Mild (<1-2 g/day) | Mild | Heavy (often >3 g/day) |
| RBC casts | Absent | Absent | PRESENT (diagnostic) |
| WBC casts | May be present | Absent | May be present |
| Muddy brown casts | Absent | PRESENT | Absent |
| WBC in urine | Elevated (13-138/µL) | Low | Low |
| Timeline | Days-weeks post-medication | Hours-days post-injury | Days-weeks |
| Classic triad | Rare | N/A | Hemoptysis possible |
Practice Questions
Question 1: A 54-year-old on omeprazole (3 months) for GERD develops AKI (Cr 1.1 to 2.8 in 1 week). Urinalysis: WBC 45/hpf, RBCs 8/hpf, protein 1+, no casts. Most likely diagnosis? A) Acute tubular necrosis B) Acute interstitial nephritis C) Rapidly progressive glomerulonephritis D) Prerenal AKI
Answer: B) Acute interstitial nephritis. The timeline (3-month PPI use with recent AKI), nonoliguric pattern (Cr rise despite presumably preserved urine output), elevated WBCs in urine without casts, and mild proteinuria are classic for drug-induced AIN. PPIs are 2nd-most common drug cause of AIN. Absence of RBC casts excludes RPGN. The absence of muddy brown casts argues against ATN.
Question 2: A 32-year-old woman presents with red eyes (bilateral anterior uveitis, confirmed by ophthalmology) and AKI (Cr 2.1). Urinalysis: WBCs, mild proteinuria, no RBC casts. Urine B2M elevated. Most likely diagnosis? A) Goodpasture syndrome B) Systemic lupus erythematosus C) TINU syndrome D) Medication-induced AIN only
Answer: C) TINU syndrome. The combination of bilateral anterior uveitis (ocular finding) + AIN (renal finding) + elevated B2M = TINU syndrome diagnosis. This is the specific scenario where B2M has excellent diagnostic utility. Goodpasture would present with hemoptysis and RBC casts. SLE possible but bilateral uveitis less typical.
Question 3: A 68-year-old on amoxicillin (day 7) develops AKI. Biopsy confirms AIN. Current Cr is 3.2 (baseline 1.0). Which statement represents best management? A) Discontinue amoxicillin and observe; most cases self-limited B) Discontinue amoxicillin + start prednisone immediately (within first 2-3 weeks) C) Discontinue amoxicillin + start dialysis; steroids contraindicated in infections D) Continue amoxicillin (needed for infection); add corticosteroids for kidney protection
Answer: B) Discontinue amoxicillin + start prednisone immediately (within first 2-3 weeks). Antibiotic-induced AIN requires both: (1) drug discontinuation AND (2) corticosteroids if started early. Early steroid therapy (within 1-3 weeks) improves outcomes (49% complete recovery vs lower rates if delayed). Continuing the offending drug defeats the purpose. Dialysis may be needed for complications, but shouldn’t delay appropriate therapy.
Key Takeaways
- AIN accounts for 15-27% of biopsy-proven AKI — must maintain high suspicion
- Classic triad absent in 2/3 of cases — don’t rely on fever/rash/eosinophilia
- Nonoliguric AKI + new medication = suspect AIN until proven otherwise
- Urine eosinophils unreliable (outdated test; don’t order)
- CXCL9 emerging biomarker for non-invasive AIN diagnosis
- Discontinue offending agent immediately — most critical intervention
- Early corticosteroids improve outcomes if started within 2-3 weeks
- TINU is not just pediatric — affects adults; requires ophthalmology screening
See Also
Clinical Content (01-Clinical-Medicine/Nephrology)
- AKI Hub - Full Clinical Reference
- Essential Renal Laboratory Tests
Butler-COM Resources
- Butler COM - Nephrology Deep Dive